INTERPLAY BETWEEN CANNABINOIDS AND INFLAMMATORY CYTOKINES IN HUMAN BREAST CANCER

C. PISCOPO, M.C. PROTO, A.M. CASCONE, P. ZEPPA, D. FIORE, B.M. FUSCO, M. BIFULCO, P. GAZZERRO

Article ID: 6422
Vol 32, Issue 4S1, 2018
DOI: https://doi.org/10.54517/jbrha6422
Received: 8 September 2018; Accepted: 8 September 2018; Available online: 8 September 2018; Issue release: 8 September 2018

Abstract

Breast cancer is a highly heterogeneous disease and one of the few tumour types molecularlycharacterized. While luminal and human epidermal growth factor receptor 2 positive (HER2+) tumourscan be controlled by hormonal and anti-HER2 interventions, the triple-negative breast cancers (TNBC)are resistant to standard treatments. Since the tumour microenvironment is an important player in breasttumour progression, the stromal components could represent a source of new prognostic biomarkers andtargets for potential therapeutic strategies mainly in tumors lacking molecular sites of intervention. Wepreviously found that Met-F-AEA, agonist at cannabinoid receptor 1 (CB1) inhibited cell migration andepithelial-mesenchymal transition of the TNBC cell line MDA-MB-231, through modulation of MMP2and Wnt/ß-catenin signaling, respectively.



References

Supporting Agencies



Copyright (c) 2018 C. PISCOPO, M.C. PROTO, A.M. CASCONE, P. ZEPPA, D. FIORE, B.M. FUSCO, M. BIFULCO, P. GAZZERRO




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).